Hiroaki Nagano

Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

Pancreatic cancer (PC) is an aggressive and lethal tumor with a poor prognosis. FOLFIRINOX improves the prognosis of patients with PC; however, despite UGT1A1 screening, adverse events, such as severe neutropenia, occur frequently. This study aimed to identify the novel biomarkers of severe neutropenia in patients treated with modified FOLFIRINOX (mFFX) for PC. In this study, patients with PC treated with mFFX ( n = 71) and gemcitabine plus nab‐paclitaxel (GnP) ( n = 92) and patients with colorectal cancer treated with FOLFOXIRI ( n = 50) were included. Genome‐wide screening using whole‐exome sequencing was performed during the screening phase. Validation analysis was performed using polymerase chain reaction genotyping, the Cochran–Armitage trend test, and multivariate analysis. The diagnostic performance of combined risk factors for severe neutropenia was examined using logistic regression with leave‐one‐out cross‐validation. Three gene polymorphisms were selected from the screening phase and subjected to the validation phase. In the validation phase, a single nucleotide polymorphism in C11orf24 (c.448C>T, rs901827) was significantly correlated with ≥ Grade 3 neutropenia in mFFX and FOLFOXIRI but not in GnP. Multivariate analysis showed C11orf24 and baseline neutrophil count as independent risk factors for ≥ Grade 3 neutropenia. The diagnostic performance of the neutropenia prediction model showed areas under the curve of 0.754 (sensitivity = 0.605, specificity = 0.848) and 0.856 (sensitivity = 0.800, specificity = 0.893) for ≥ Grade 3 and 4 neutropenia, respectively. The C11orf24 gene and baseline neutrophil count may be useful biomarkers for predicting severe neutropenia following irinotecan‐containing triplet chemotherapy.

Year:

2025

Aim This study aimed to investigate the efficacy of radical resection and postoperative adjuvant chemotherapy on the survival benefit in patients with pancreatic ductal adenocarcinoma (PDAC), stratified by age, frailty, and other factors in actual clinical practice. Methods We retrospectively analyzed the clinicopathological and follow‐up data of 414 patients with PDAC who underwent surgical resection at nine institutions under the Yamaguchi Pancreat/Biliary Disease Study Group, between January 1997 and December 2016. Recurrence‐free survival (RFS) and overall survival (OS) were calculated using the Kaplan–Meier method. Associations between survival and prognostic factors were evaluated by univariate and multivariate analyses. Results There were 30.5% of patients with PDAC who were aged < 65 years, 37.9% aged 65–74 years, 17.6% aged 75–79 years, and 14.0% aged ≥ 80 years. Notably, RFS declined with increasing age (median RFS: 12.9, 10.2, 9.4, and 7.4 months, respectively), although the differences were not significant ( p = 0.223). OS significantly decreased with age (median OS: 21.6, 21.2, 17.0, and 13.9 months, respectively; p = 0.005). In patients aged < 75 years, independent prognostic factors identified by univariate and multivariate analyses included lymph node metastasis (hazard ratio [HR], 1.598; p = 0.007), tumor size (HR, 1.489; p = 0.043), R status (HR, 1.536; p = 0.011), and serum albumin levels (HR, 1.526; p = 0.031). In patients aged ≥ 75 years, a high modified frailty index (HR, 2.446; p = 0.012) emerged as an independent prognostic factor, along with lymph node metastasis, CA19‐9 level (HR, 1.897; p = 0.017), and R status (HR, 2.087; p = 0.007). Conclusion The prognosis for older patients with PDAC was shorter than that of younger patients. Frailty may contribute to their poorer prognosis in older age.

Year:

2025

In vitro responses of autologous Conv. and 7 × 19 CAR-T against patient-derived pancreatic cancer organoids. A, Surface expression of endogenous HER2 was assessed in patient-derived pancreatic cancer organoids by flow cytometry. Open and filled histograms indicate staining with humanized anti-HER2 Ab and nonstaining, followed by anti–human IgG Ab, respectively. B–D, Anti-HER2 Conv. or 7 × 19 CAR-T or UTD was cocultured with HER2-positive pancreatic cancer organoids at an effector to target (E:T) ratio of 1:1 for 4 days. B, Morphologic images after 4 days of coculture. C, The number of residual tumor cells after coculture was analyzed by flow cytometry. Data are shown as mean ± SD of triplicate samples. D, The supernatants were harvested after 4 days of coculture, and the concentration of IFNγ was assessed by ELISA. Data are shown as mean ± SD of triplicate samples. **, P P

Year:

2024

The diversity of TCR repertoire in T cells before and after the injection of 7 × 19 CAR-T. 7 × 19 CAR-T cells generated from PBMC were sorted into CAR-positive or -negative T cells and analyzed for repertoire of TCRα and TCRβ chains (before injection). Spleen cells were harvested from the mice which rejected U87MG EGFRvIII by the injection of anti-EGFRvIII 7 × 19 CAR, 42 days after tumor inoculation. Spleen cells were sorted into CAR-positive or -negative T cells for analysis of TCRα- and TCRβ-chain repertoire (after injection). TCR repertoire was analyzed using the next-generation sequencer, and the frequencies of V and J region usage were displayed as 3D graphs. The numbers in the graphs represent the diversity index calculated as Shannon–Weaver index H (a lower number indicates a less diversity). Representative data from three samples per group are shown.

Year:

2024

Potent therapeutic effects of patient’s PBMC-derived 7 × 19 CAR-T in autologous pancreatic cancer organoids. A, Tumor mass was established in NOG-ΔMHC by subcutaneous inoculation with 1 × 10 6 pancreatic cancer organoids. After 88 days, the established tumor mass was resected and examined for HER2 expression by IHC staining. B and C, NOG-ΔMHC mice were inoculated subcutaneously with 1 × 10 6 pancreatic cancer organoids on day 0 and then treated with intravenous injection of 5 × 10 6 anti-HER2 Conv. CAR-T or 7 × 19 CAR-T cells on day 10 or (left) untreated. Thereafter, the tumor size ( B ) and the mouse survival ( C ) were assessed ( n = 5 each in all groups, biological replicates). **, P P

Year:

2024

Potent therapeutic effects of 7 × 19 CAR-T in the preestablished solid tumor model of human glioblastoma. NOG-ΔMHC mice were inoculated subcutaneously with 3.5 × 10 6 U87MG EGFRvIII tumor cells on day 0 and then treated with intravenous injection of 1 × 10 7 Conv. CAR-T, 7 × 19 CAR-T, or UTD on day 10. Thereafter, the tumor size ( A ) and the mouse survival ( B ) were assessed ( n = 12 each in UTD and 7 × 19 CAR-T groups; n = 13 in Conv. CAR-T group; n values are biological replicates). In A , each line indicates the tumor volume of an individual mouse. Tumor volumes during the initial 56 days of 7 × 19 CAR-T–treated mice are shown in the inset. ***, P

Year:

2024

Massive infiltration of T cells and tumor cell lysis in the tumor tissues by the treatment with 7 × 19 CAR‐T. NOG‐ΔMHC mice were inoculated subcutaneously with 3.5 × 10 6 U87MG EGFRvIII cells on day 0, followed by intravenous injection of 1 × 10 7 UTD, Conv. CAR‐T, or 7 × 19 CAR‐T cells on day 10. Tumor tissues were resected from the mice on day 13 to prepare formalin-fixed, paraffin-embedded slices for H&E and IHC staining using rabbit anti–human CD4, CD8, CCR7, caspase-3 mAbs and mouse anti–human EGFRvIII mAb. Stained cells were visualized and observed by microscopic examinations at ×100 and ×400 magnifications. A, Representative images are displayed. Scale bar indicates a length of 200 μm (×100) or 50 μm (×400). B, The number of stained cells per tumor area (mm 2 ) or the percentage of the stained area was calculated using BZ‐X analyzer software. Data are shown as mean ± SD of triplicate samples ( n = 3 each per group, biological replicates). *, P P P

Year:

2024

EGFRvIII-specific immune responses of Conv. CAR and 7 × 19 CAR-T cells in vitro . A, Surface expression of EGFRvIII was assessed in U87MG glioblastoma cell lines by flow cytometry. Open and filled histograms indicate staining with anti-EGFRvIII Ab and nonstaining, followed by anti–mouse IgG Ab, respectively. B and C, Conv. CAR-T, 7 × 19 CAR-T, or UTD T cells were cocultured with the indicated tumor cells at an effector-to-target (E:T) ratio of 1:1 and 1:5 for 2 days. The number of residual tumor cells ( B ) and T cells ( C ) after coculture was analyzed by flow cytometry. Data are shown as mean ± SD of triplicate samples. D, The supernatants of the coculture described in B were harvested, and the concentration of IFNγ was assessed by ELISA. Data are shown as mean ± SD of triplicate samples. **, P P

Year:

2024

Cancer immunotherapy using immune checkpoint inhibitors and its combination with other anticancer therapies has emerged as a new standard of care because of the encouraging therapeutic effects in various solid cancers. Nonetheless, glioblastoma and pancreatic cancer remain resistant to immunotherapy and represent intractable cancers with the poorest prognosis. We investigated the therapeutic effects of next-generation chimeric antigen receptor (CAR) T cells producing IL7 and chemokine (C–C motif) ligand 19 (CCL19; referred to as 7 × 19 CAR-T) in these intractable cancers. Cytotoxic activities and therapeutic effects of 7 × 19 CAR-T were evaluated in vitro and in vivo , in a model using EGFR variant III (EGFRvIII)–positive glioblastoma and anti-EGFRvIII CAR-T generated from healthy donor peripheral blood mononuclear cells (PBMC), or a model using HER2-positive pancreatic cancer organoids and anti-HER2 CAR-T generated from the same patient’s PBMC. Anti-EGFRvIII 7 × 19 CAR-T exhibited cytotoxic activity specific to EGFRvIII-positive tumor, induced complete rejection of glioblastoma with massive T-cell infiltration and tumor cell death in the tumor tissues, and consequently prolonged mouse survival. Anti-HER2 7 × 19 CAR-T demonstrated a potent cytotoxic activity against autologous HER2-positive pancreatic cancer organoids and induced complete rejection of autologous tumor along with prolonged mouse survival. Our results suggest that 7 × 19 CAR-T could become a therapeutic option for glioblastoma and pancreatic cancer. To the best of our knowledge, this is the first study to demonstrate the therapeutic efficacy of next-generation CAR-T in an autologous model using patient-derived tumor organoids and CAR-T generated from the same patient’s PBMC, in which unwanted allogeneic immune responses are fully excluded. Significance: Despite the clinical development of CAR T-cell therapy, its efficacy in solid cancers has yet to be established. This study explored the therapeutic potential and immunologic mechanisms of IL7/CCL19-producing CAR-T therapy in preclinical solid cancer models of glioblastoma and pancreatic cancer. We found that IL7/CCL19-producing CAR-T cells generated from the patient’s PBMC showed potent therapeutic effects against the solid cancer model established by inoculating organoids from the autologous tumor tissue.

Year:

2024

The diversity of TCR repertoire in T cells before and after the injection of 7 × 19 CAR-T. 7 × 19 CAR-T cells generated from PBMC were sorted into CAR-positive or -negative T cells and analyzed for repertoire of TCRα and TCRβ chains (before injection). Spleen cells were harvested from the mice which rejected U87MG EGFRvIII by the injection of anti-EGFRvIII 7 × 19 CAR, 42 days after tumor inoculation. Spleen cells were sorted into CAR-positive or -negative T cells for analysis of TCRα- and TCRβ-chain repertoire (after injection). TCR repertoire was analyzed using the next-generation sequencer, and the frequencies of V and J region usage were displayed as 3D graphs. The numbers in the graphs represent the diversity index calculated as Shannon–Weaver index H (a lower number indicates a less diversity). Representative data from three samples per group are shown.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (7)

Takashi Ohama

-

JAPAN
View details

Teijiro Hirashita

Oita University

JAPAN
View details

Hiroyuki Yasuda

Keio University

JAPAN
View details

Susumu Eguchi

Professor

Nagasaki University

JAPAN
View details

Atsushi Nanashima

-

JAPAN
View details

Taro Takami

Yamaguchi University

JAPAN
View details

Koji Tamada

-

JAPAN
View details